Generic Drugs Conference In Riyadh Highlights Empowering Local Pharmaceutical Manufacturing And Investment Opportunities

The Saudi Food and Drug Authority has wrapped up the Generic Drugs Conference in Riyadh, spotlighting the theme "Empowering Local Pharmaceutical Manufacturing," and stressing generic medicines as a pillar of Saudi Arabia’s healthcare system and economic diversification, with speakers linking the event’s outcomes to the goals of Saudi Vision 2030 and to efforts to expand reliable access to affordable treatments.

Officials, investors and experts said the conference outcome should help speed up patient access to essential medicines, while keeping quality and safety central, as participants urged structured cooperation between regulators, manufacturers and healthcare providers so that feedback from hospitals and industry contributes to future SFDA rules and supports long-term stability in the pharmaceutical market.

The two-day agenda at the SFDA headquarters gathered SFDA Chief Executive Officer Dr. Hisham Aljadhey alongside representatives of regulatory agencies, pharmaceutical companies, healthcare institutions, investors and academic specialists, who joined scientific sessions and panel discussions that examined how the pharmaceutical sector is responding to rapid technological change across research, production, regulation and supply chains.

Speakers presented a wide range of investment opportunities in the Kingdom’s pharmaceutical field, pointing to growing government incentives for both local and international investors, while noting that these incentives are designed to attract new capital, support manufacturing capacity for generic medicines, and enhance Saudi Arabia’s role in regional and global medicine supply networks.

Several sessions focused on aligning the development of generic drugs with the strategic objectives of Saudi Vision 2030, as experts discussed how a stronger local manufacturing base can reduce reliance on imported medicines, support national resilience during health crises, and contribute to non-oil economic growth by creating skilled jobs in the pharmaceutical and biotechnology industries.

Participants highlighted the need for close coordination between national and international regulatory authorities to build public and clinical confidence in generic medicines, stressing that consistent standards, transparent data and harmonised guidelines help healthcare professionals trust generic products, and also assist companies in planning investments that meet Saudi and global regulatory expectations.

Another core topic was the role played by hospital drug lists and procurement policies in promoting generic drug use, with specialists explaining that updated formularies, clear pricing policies and value-based purchasing can encourage hospitals and healthcare providers to choose approved generics, provided that these products meet strict SFDA standards on safety, quality and therapeutic equivalence.

During the closing session, speakers underlined that continued collaboration between the SFDA, the pharmaceutical industry and healthcare providers is essential to support innovation in generic drug development, improve the speed of regulatory review where possible, and ensure that regulations evolve in response to scientific progress while continuing to protect patients across Saudi Arabia.

By drawing attention to investment opportunities and regulatory priorities, the Generic Drugs Conference reinforced the SFDA’s role as a scientific authority, and showed how the Saudi pharmaceutical sector can support sustainable healthcare, economic diversification and the broader objectives of Saudi Vision 2030 through a stronger ecosystem for generic medicines and local manufacturing.

With inputs from SPA